Home Cart Sign in  
Chemical Structure| 1532593-30-8 Chemical Structure| 1532593-30-8

Structure of ML355
CAS No.: 1532593-30-8

Chemical Structure| 1532593-30-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ML355 is a selective 12-lipoxygenase inhibitor with an IC50 value of 0.34 µM, with much less potency against 15-LO-1, 15-LO-2, and 5-LO (IC50s = 9.7, >100, and >100 µM).

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of ML355

CAS No. :1532593-30-8
Formula : C21H19N3O4S2
M.W : 441.52
SMILES Code : O=S(NC1=NC2=CC=CC=C2S1)(C3=CC=C(NCC4=CC=CC(OC)=C4O)C=C3)=O
MDL No. :MFCD28167822
InChI Key :OWHBVKBNNRYMIN-UHFFFAOYSA-N
Pubchem ID :70701426

Safety of ML355

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Human platelets 25 µM ML355 treatment significantly decreased 12-HETE formation in thrombin-stimulated human platelets. PMC5620123
Human platelets 25 µM 5 min ML355 (25 µM) more potently inhibited thrombin-mediated platelet aggregation compared to aspirin (ASA, 100 µM). The combination of ML355 and ASA did not result in an additive inhibitory effect. PMC5620123
Human platelets 100 µM 5 min ML355 (100 µM) strongly inhibited platelet aggregation induced by PAR1-AP, PAR4-AP, and collagen, and the inhibitory effect diminished with decreasing concentration of ML355. PMC5620123
Human platelets 25, 50, 100 µM 5 min ML355 dose-dependently inhibited human platelet aggregation induced by thrombin. At low thrombin concentration (0.25 nM), ML355 completely blocked platelet aggregation; at 0.5 nM thrombin, ML355 inhibited 50-60% of platelet aggregation; at 1 nM thrombin, ML355 inhibited about 25% of platelet aggregation. High concentrations of thrombin (>2.5 nM) could reverse the inhibitory effect of ML355. PMC5620123
AML12 cells 50 μM 24 h Simulated the fatty liver environment with IRI in vitro, showing a significant increase in 12-HETE levels. PMC6909624
Mouse platelets 50 µg/ml 5, 15, 30, 60 min To study the uptake of sHDL by mouse platelets, results showed that sHDL was internalized by platelets within 5 min and reached saturation after 15 min. PMC7821904
Human platelets 10 µM 15 min To investigate the inhibitory effect of ML355-sHDL on human platelet aggregation, results showed that ML355-sHDL exhibited the strongest inhibition of platelet aggregation. PMC7821904
HK-2 cells 100 μg/mL 24 h To evaluate the inhibitory effect of ML355 on GEN-induced oxidative stress, results showed that ML355 significantly reduced ROS generation. PMC8986073

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
DBA2 mice LUSC xenograft model #VALUE! 3 mg/kg Once daily for 24 days ML355 significantly inhibited L1-FGGY-driven tumor growth and reversed the immunosuppressive microenvironment. PMC9288060
C57BL/6 mice Fatty liver model Intraperitoneal injection 3 mg/kg Single dose, continued until the end of the experiment ML355 reduced HCC recurrence in fatty liver by inhibiting the ALOX12-12-HETE pathway. PMC6909624
Mice Laser-induced cremaster arteriole thrombosis model Intravenous injection 1.5 mg/kg Single dose, lasting 24 hours To investigate the inhibitory effect of ML355-sHDL on thrombus formation in mice, results showed that ML355-sHDL significantly inhibited thrombus formation without impairing normal hemostasis. PMC7821904
Mice FeCl3-induced mesenteric arteriole thrombosis model and laser-induced cremaster arteriole thrombosis model Oral 15 mg/kg, 30 mg/kg Twice daily for two days ML355 treatment significantly impaired thrombus growth and vessel occlusion. In the FeCl3-induced mesenteric arteriole injury model, platelet adhesion, aggregation, and thrombus formation were impaired in ML355-treated mice, and the thrombi were unstable and frequently embolized. In the laser-induced cremaster arteriole thrombosis model, ML355 (3.5 mg/kg and higher doses) significantly inhibited thrombus formation, and the thrombi were smaller and unstable. ML355 had minimal impact on hemostasis, with no significant increase in hemostatic plug formation or bleeding. PMC5620123
Mice MIOX-Tg mice Intraperitoneal injection 3 mg/kg Once daily for 7 days To evaluate the protective effect of ML355 on GEN-induced kidney injury, results showed that ML355 significantly reduced tubular injury and inflammatory response. PMC8986073
Spontaneously hypertensive rats (SHR) Renal ischemia-reperfusion injury model Intraperitoneal injection 30 mg/kg Every other day up to 7 days ML355 treatment lowered levels of 12-HETE, resulting in reduced renal lipid peroxidation, ER stress, tubular cell death, and inflammation, and improved renal function recovery. PMC10696802

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.26mL

0.45mL

0.23mL

11.32mL

2.26mL

1.13mL

22.65mL

4.53mL

2.26mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories